Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFENCE gut immune phenotyping during immune checkpoint inhibitor therapy
NL-OMON55053Suspended
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of CTLA4 antibody in cancer, sponsored by University Medical Center Groningen. Started Oct 2021; status: suspended.
02
Drugs
CTLA4 antibody
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON55053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55053.